Cisplatin for triple negative breast cancer
WebJan 4, 2024 · Triple-negative breast cancers (TNBCs) have shown sensitivity to decitabine; however, the underlying mechanism of its anticancer effect and its effectiveness in treating TNBCs are not fully understood. We analyzed the effects of decitabine on nine TNBC cell lines and examined genes associated with its cytotoxic effects. WebJul 22, 2024 · Cisplatin represents a promising chemotherapeutic compound in neoadjuvant approaches and in the metastatic setting, but its use is limited by scarce bioavailability, severe systemic side effects and drug resistance. Novel site-directed aptamer-based nanotherapeutics have the potential to overcome obstacles of chemotherapy.
Cisplatin for triple negative breast cancer
Did you know?
WebKnockdown, chromatin immunoprecipitation, and reporter assays all showed that p63 regulates MFG-E8 expression, and MFG-E8 knockdowns sensitized triple-negative … WebJan 25, 2010 · Cisplatin is a chemotherapeutic agent not used routinely for breast cancer treatment. As a DNA cross-linking agent, cisplatin may be effective treatment for hereditary BRCA1 -mutated breast cancers.
WebApr 14, 2024 · Silver DP, Richardson AL, Eklund AC, et al. Efficacy of neoadjuvant cisplatin in triple-negative breast cancer. J Clin Oncol. 2024;28:1145-1153. 57. Gasparini G, Dal Fior S, Panizzoni GA, et al ... WebNov 13, 2013 · Cisplatin and paclitaxel are active in triple-negative breast cancer (TNBC). Despite different mechanisms of action, effective predictive biomarkers to preferentially …
WebCisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. WebMar 22, 2024 · The addition of rucaparib to cisplatin did not increase 2-year DFS (54.2% cisplatin vs. 64.1% cisplatin + rucaparib; P = 0.29). ... Patients with triple-negative breast cancer (TNBC) who have ...
WebTriple-negative breast cancer (TNBC) is a highly aggressive type of breast cancer lacking estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor2 (HER2), which resulted in the lack of target for treatment. 14 Up to date, drug treatment for triple-negative breast cancer still limited to cytotoxic agents such as ...
WebJan 25, 2010 · Cisplatin is a chemotherapeutic agent not used routinely for breast cancer treatment. As a DNA cross-linking agent, cisplatin may be effective treatment for … how many people are in china\u0027s militaryWebJun 15, 2024 · Introduction. As one of the main causes of female deaths, breast cancer (BC) is a heterogeneous tumor with different subtypes [1,2].Triple negative breast … how many people are in clevelandWebBetween 15–20% of all breast cancer cases are classified as triple negative breast cancers (TNBCs): Patients in this category have the highest rate of metastatic disease and the poorest prognosis [1,2].TNBC cells do not express well-established therapeutic targets including the estrogen and progesterone (ER and PR) receptors or human epidermal … how can i be administrator windows 10WebNational Center for Biotechnology Information how can i be a financial advisorWebKnockdown, chromatin immunoprecipitation, and reporter assays all showed that p63 regulates MFG-E8 expression, and MFG-E8 knockdowns sensitized triple-negative breast cancers to cisplatin treatment. Taken together, our results show that MFG-E8 is expressed in triple-negative breast cancers as a target gene of the p63 pathway, but may serve a ... how many people are in charge in an oligarchyWebApr 7, 2024 · The high frequency of homologous recombination deficiency (HRD) is the main rationale of testing platinum-based chemotherapy in triple-negative breast cancer … how can i be a contestant on family feudWebApr 3, 2024 · The chemotherapy reduces the risk of the breast cancer coming back. You usually have a combination of chemotherapy drugs that might include: doxorubicin epirubicin paclitaxel docetaxel carboplatin cisplatin Researchers are still looking into the best chemotherapy combinations. how can i be a fashion consultant